Over 20 years of Experience


Since its incorporation in 2002, Akela Consultancy Limited has provided repeat business clinical research services to the pharmaceutical and biotechnology industries.

Akela’s staff has experience over the last twenty years that includes the initiation and execution of over 60 clinical trials from single centre Phase I to global Phase III studies.

Akela is led by John Matthews, an accomplished, highly experienced, forensically trained Head of Clinical Operations with 28 years of success within the pharmaceutical / CRO sector across many therapeutic areas.

John has expertise in delivering large global clinical trials that are inspection ready and recruited on time.  John has a proven project management, global teams & office management and customer interactions competencies. John possesses strong leadership and negotiation skills with the proven ability and passion to motivate global international teams. With excellent communication, networking and matrix management abilities, John has demonstrated success directing organisational development from start-up, during dynamic growth, transition and change.

Why Us
Why Choose Akela
Clinical Research Services
Why Choose Akela

What our Clients say…


We selected a new site to participate in one of our trials. I was pleased when this site independently hired Akela to help them initiate and manage the study. Knowing that Clare and John were involved increased my level of comfort from the outset as I knew of their work from WCT. My CRAs and medical monitor have been impressed with the speed of recruitment, quality of the data and Clare’s coordination of the site. Recruitment at this site actually proved better than at the more experienced sites on the study so we awarded a second trial to them. In my opinion Akela’s input made a positive contribution to our trial.

Geoffrey Dunbar M.D., Vice President, Clinical Development and Regulatory Affairs, Targacept Inc.


Clare and John were recommended to me and have recently monitored and managed three phase I/II studies for Vantia Ltd. I found their flexible approach a great asset and our trials were set up and started in rapid time. Clare and John’s work was of the highest quality and I felt fully informed throughout the trials. Issues that arose at site level were handled professionally and in a timely manner. Their monitoring reports were excellent. The Phase I / Clinical Study Units were encouraged and motivated by Akela and produced excellent results. I recently commissioned an audit of Akela’s SOPs and they passed with flying colours. All in all it was a very successful collaboration and I am more than happy to recommend Akela

Dr Hilary McElwaine-Johnn, Chief Medical Officer, Vantia Therapeutics


I had the pleasure to work with Akela in my previous position as International Head of the CRO WCT, which was later to become i3 Research. and I grew to place much trust in them. WCT has reformed and I have already asked d John to support us providing a number of operational services, which they delivered in amazing time and quality. In my opinion John is one of the best senior project managers I have worked with. When WCT were assigned the InterSePT study he was the natural choice to lead the international team of over 100 staff and he did not let me down. I am sure WCT will need high calibre consultants from time to time in the future and Akela will be one of my first choices

Angelico Carta, MD. President, Worldwide Clinical Trials (WCT)

previous arrow
next arrow